Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVADEX ECP in Refractory Crohn's Disease
NCT00221026Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Dec 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of methoxsalen in Crohn's disease, sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Crohn's Disease Activity Index at 12 weeks. Started Dec 2004; status: completed.
02
Drugs
methoxsalen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00221026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221026.